Frequently Asked Questions about Passive cancer Immunotherapy and its Major limitations.

If you’re a cancer patient and you’re researching how passive immunotherapy can help you combat the cancerous tumor and you have many questions about its effectiveness and itslimitations, then this article will give you a brief idea about, its most widely used application and the major limitations of it.

So what is passive immunotherapy?

It is mainly the modification of the immune system responses to be able to produce a certain type of result, in this case the attack of the cancerous tumor, but there are 2 types of it: active and passive.

The passive type goes about its effectwithout needing the immune system to be actively used for it to operate as opposed to the active type that totally requires that immune system to be active and fully operational for the effect to occur.

Can you explain further what you mean about the passive type?

Sure, as an example, the most widely used application of it is called monoclonal antibody immunotherapy, and this type is made from antibodies that are designed outside the patient’s body and then re-introduced into it once again, and thus it doesn’t need the immune system to make them, as they’re already made, thus their dependency is not on the immune system, it’s on these types of antibodies.

They’re widely used, but are they effective?

Well despite being widely used, they are not as successful as expected.

How so?

Well to understand that you need to understand its limitations in the first place.

Okay, so what are the major limitations for this type of therapy?

Among the expectations blown is that nothing is really as it seems, sometimes the products weren’t as specific as noted or as pure, things that didn’t appear to be toxic, became toxic especially at higher doses, but to be more specific.

For example, most of the oncologists prescribe this treatment not as a first line of therapy, but go for it after treatments like chemotherapy or radiation therapy, and after these destructive therapies, many things could happen that could decrease the effectiveness completely, because these therapies could lead to the change of the antigens and if you’re targeting a specific antigen protein that’s not the same anymore, it’s ineffective.

Also usually the immune system is too worn out from all these destructive approaches, and thus this could lead to a 20-30% effectiveness only.

Finally the toxicity especially in certain high doses can be dangerous.

And thus this wraps up our exposure to the world of passive immunotherapy for cancer treatments and its major limitations.

Be in touch with Global Allied Pharmaceuticals to explore more on Cancer related assistance. We are privileged to serve you. Kindly visit www.gapsos.com for further queries.